Showing 6611-6620 of 7463 results for "".
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Merkel Cell Carcinoma Is On The Risehttps://practicaldermatology.com/news/merkel-cell-carcinoma-is-on-the-rise/2457879/Merkel cell carcinoma (MCC) is on the rise, according to new research published in the Journal of the American Academy of Dermatology and presented at the American Academy of Dermatology 2018 Annual Meetin
- FDA Grants Priority Review for Genentech's Rituxan for Pemphigus Vulgarishttps://practicaldermatology.com/news/fda-grants-priority-review-for-genentechs-rituxan-for-pemphigus-vulgaris/2457883/The FDA has accepted Genentech’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) for the treatment of pemphigus vulgaris (PV). Genentech is a member of the Roche Group. <
- Biofrontera Rings Nasdaq Market Closing Bellhttps://practicaldermatology.com/news/biofrontera-rings-nasdaq-closing-bell/2457881/Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- South Beach Symposium to Kick Off March 1https://practicaldermatology.com/news/south-beach-symposium-to-kick-off-march-1/2457895/Now celebrating its 16th year, the 2018 South Beach Symposium (SBS) will feature live demonstration workshops of minimally invasive aesthetic treatments with injectables and devices providing attendees with new skills and techniques th
- Prestige Beauty Industry Grows to $17.7Bhttps://practicaldermatology.com/news/prestige-beauty-industry-grows-to-177b/2457900/The US prestige beauty industry reached $17.7 billion in 2017, a six percent increase over 2016, according to global information company The NPD Group. The skincare category led in growth with a nine percent increase in sales that contributed 45 percent of t
- Seeing Scars: Patients and Doctors Often Disagree in Evaluating Surgical Scarringhttps://practicaldermatology.com/news/seeing-scars-patients-and-doctors-often-disagree-in-evaluating-surgical-scarring/2457902/Patients and doctors often don’t assess scar severity the same way, a new study in JAMA Facial and Plastic Surgery suggests. Researchers from the Perelman School of Medicine at the U
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factor